Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
Discover
Back to filter
Show all topics (10)
Related topics
Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer
Nov 29, 2021
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
Accelerating AML Research Through Single-cell Multi-omics- integrate seamlessly into existing NGS
Nov 25, 2021
Dr. Linde Miles Memorial Sloan Kettering Cancer Center about her research, use of the Tapestri as a single-cell...
Discover the advanced Detector Technology in Agilent NovoCyte flow cytometers
Nov 18, 2021
This technical overview describes advancements in detector technology, and highlights examples where optimal signal...
WEBINAR: Recent Advancements In Neurodegenerative Biomarkers
Sep 6, 2021
Recent Advancements in Neurodegenerative Biomarkers: Progress Towards a Diagnostic Blood Test for Alzheimer’s Disease
How to Improve Your Viral Nucleic Acid Extraction Processes
Sep 6, 2021
High-Throughput Extraction with CyBio FeliX
Introducing New Aura 4.0 software
Aug 31, 2021
With new features for both acquisition & analysis Aura Software enables you to capture and analyze your data quickly,...
Comparison of gamma and x-ray irradiation results
Aug 12, 2021
Biological effects of Cs-137 and X-ray irradiators are comparable with regards to...
Hypoxia further exacerbates myopathy in broilers via alteration of satellite cell fate
Aug 2, 2021
Woody breast (WB) condition has created a variety of challenges for the global poultry...
High quality Bioluminescence and X-Ray analysis in lung squamous cell carcinoma
Jul 21, 2021
Spectral Instruments Imaging provides unrivaled sensitivity for bioluminescence,...
Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility
Jul 15, 2021
6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full...
De novo design of a biologically active amyloid
Feb 5, 2018
Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. Gallardo et al. designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. They found that amyloid toxicity is observed only in cells that both express VEGFR2 and are dependent on VEGFR2 activity for survival. Thus, amyloid toxicity here appears to be both protein-specific and conditional—determined by VEGFR2 loss of function in a biological context in which target protein function is essential.
Brand profile
